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Purpose: To study the physical properties and dissolution profiles of commercial samples of 
artesunate and amodiaquine tablets. 
Methods: Fifteen generic brands of artesunate and five generic brands of amodiaquine tablets were 
obtained from drug retail outlets in Oyo and Ogun States in southwestern Nigeria. The tablets were 
subjected to various compendial tests including identification, weight uniformity, uniformity of content, 
content of active ingredient and uniformity of diameter. Additional tests used as a basis for the 
assessment of the pharmaceutical equivalence of the products include hardness, disintegration time and 
dissolution rate. Data obtained were analysed by correlation analysis, Chi-square and ANOVA.  
Results: Thirteen generic brands of artesunate (87 %) and four amodiaquine brands (80 %) 
investigated were imported. Two brands of the imported artesunate brands were found to contain 
undetectable amount of artesunate while another 8 samples contained overages. All the amodiaquine 
brands passed the assay test as stipulated by United States Pharmacopoeia (USP) for amodiaquine 
tablets while tablet disintegration time of amodiaquine products ranged from 5.8 – 20.7 min. All but one 
artesunate sample passed the disintegration test too. A majority of the artesunate brands tested had 
significantly different dissolution profiles (p < 0.05). Four (80 %) of the amodiaquine tablet brands tested 
had similar dissolution profiles and percent drug released within 30 min (p > 0.05). One amodiaquine 
brand demonstrated poor dissolution profile as it did not meet minimum dissolution requirements within 
30 min.  
Conclusion: The detection of substandard artesunate tablets and a poorly formulated amodiaquine 
tablet amongst the few sample brands studied highlights the need for increased drug surveillance and 
monitoring of the qualities of antimalarial medicines currently in use in order to prevent widespread 
treatment failure.   
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INTRODUCTION 
 
Artemisinin-based therapies are a major 
breakthrough in the clinical management of 
malaria. The problem of faking and 
adulteration of antimalarials may constitute a 
major hindrance to the attainment of effective 
drug-based health care delivery. Artesunate 
is an artemisinin-based antimalarial drug 
which is indicated in the treatment of acute, 
uncomplicated, severe and resistant malaria. 
 
By 2006, 39 countries in Africa had revised 
their national drug policies to incorporate 
artemisinin combination therapy (ACT) into 
malaria case-management guidelines [1]. 
Oral artesunate can be used alone (in non-
resistant malaria) or also in combination with 
other long acting antimalarials such as 
amodiaquine, mefloquine, sulfadoxine/ 
pyrimethamine or lumenfantrine to achieve 
ACT. As a result of the short half-life of 
artemisinin derivatives, their use as 
monotherapy requires daily doses over a 
period of 7 days. Combination of one of these 
drugs with a longer half-life antimalarial drug 
allows a reduction in the duration of 
antimalarial treatment while at the same time 
enhancing efficacy and reducing the 
likelihood of resistance development to the 
two agents [2]. The availability of numerous 
brands of this artesunate in the Nigerian drug 
market today places clinicians and 
pharmacists in a difficult situation of choice of 
a suitable brand and/or alternatives.  
 
Furthermore, there are growing concerns that 
the various artesunate formulations may have 
different bioavailability and that development 
of resistance will be accelerated if suboptimal 
doses are consumed [3,4]. Reports of 
distribution of counterfeit artesunate tablets in 
south-east Asia are of great public health 
concern [5]. It is believed that each year, 300-
500 million people in Asia and Africa are 
infected with Plasmodium falciparum malaria 
and approximately 1.5 million die [6]. Control 
of malaria, which is dependent on effective 
antimalarial drugs and bed nets, has been 
hampered by a widespread increase in the 
prevalence of drug-resistant malaria para-
sites [7]. 
 
As effective as artesunate is, it is becoming 
the target of an extremely sophisticated and 
prolific counterfeit drug trade that includes the 
counterfeiting of both artesunate tablets and 
packaging, with fake products looking very 
similar to authentic ones [8,9]. The inability of 
a large section of the populace in resource-
limited countries to afford the relatively more 
expensive branded products, as well as slack 
domestic drug law enforcement, are factors in 
the infiltration of branded artesunate and 
amodiaquine tablets of doubtful quality. The 
need, therefore, to monitor the physico-
chemical and biopharmaceutical qualities of 
the generic antimalarial agents cannot be 
over-emphasized. The present study is 
designed to determine the relative 
physicochemical quality of the various 
generic and branded artesunate (50 mg) and 
amodiaquine (153.1 mg and 200 mg) tablets 
in a section of the Nigerian market in order to 
ascertain their biopharmaceutical equiva-







Artesunate reference powder was a donation 
from Greenlife Pharmaceuticals Nigeria Plc, 
(Lagos, Nigeria)   and amodiaquine reference 
powder was donated by Pfizer Specialties 
Ltd, (Lagos, Nigeria). Sodium hydroxide, 
hydroxylamine hydrochloride, ethanol, 
acetone, ethyl acetate, toluene, methanol, 
ferric chloride (all of analytical reagent grades 
from BDH, Poole, England); Hardness Tester 
(BTB 301 Pharmatest, Switzerland); Erweka 
tablet disintegration apparatus (Erweka, 
Apparabetau, Germany); Erweka DT-D 
dissolution test apparatus (Erweka, U.K.); 
TLC plates (Merck, Germany); UV-VIS 
spectrophotometer (Hitachi, Japan) were 
used in this study. 
 
Samples of different brands of artesunate 50 
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mg and amodiaquine HCl (153.1 mg and 200 
mg) tablets were randomly purchased from 
pharmacy retail outlets in southwestern 
Nigeria all samples were within their shelf-life. 
The purchase costs were noted. Fifteen 
samples that cut across 9 different artesunate 
brands (designated A-I) and five different 
amodiaquine brands (AA, BB, CC, DD, EE) 
were randomly selected for this study. 
Randomization  was done in the  proportion 
of 50:30:20 (Lagos:Ogun:Oyo states).  
 
Subjective physical assessment of 
products  
 
The labels, external packages, unique 
identification marks, leaflet inserts, foils and 
tablets were carefully examined for unique 
markings, odour and colour by all three 
authors of this work. Decisions were based 
on agreement among at least two out of the 
three assessors. For colour assessment, the  
tablets were placed on a white sheet of paper 
and both sides of each tablet examined. 
Identification of the white colour (for 
artesunate) and yellow colour (for 
amodiaquine) was carried out by matching 
with the closest colour in Federal Standard 
Number 595 colours (10). Deviations from the 
chosen colours were rated from a scale of 1 - 
10 with 10 being the chosen white and yellow 




The tablets were odourless if they were not 
flavoured. 
 
Weight uniformity test and Uniformity of 
diameter 
 
Evaluation of tablet weight variation was 
carried out using the weight uniformity test 
outlined in the British Pharmacopoeia [11]. 
Twenty tablets were randomly selected for 
each brand evaluated and their weights 
determined. The mean weight and deviation 
(%) were calculated. 
 
A micrometer screw gauge (SMC 20326, 
Sterling Manufacturing Company, India) was 
used to measure the diameter of 12 randomly 
selected tablets. The mean diameter and 
deviation (%) from the mean were calculated. 
 
Identity test for artesunate and 
amodiaquine 
 
Artesunate in the tablets were identified using 
methods B, C and D of International 
Pharmacopoeia (IP) [12] based on a 
validated TLC-Thin Layer Chromatography.  
 
Method B: Silica gel was used as the coating 
substance and a mixture of 5 volumes of 
ethyl acetate and 95 volumes of toluene was 
used as the mobile phase. Solution A was 
prepared as follows: a quantity of the 
powdered tablets, equivalent to about 0.1 mg 
of artesunate, was mixed well with 
dehydrated ethanol and filtered through a 
Whatman no.1 filter paper, discarding the first 
few mL of the filtrate. The filtrate was  
evaporated and the residue dissolved in 1.0 
ml of toluene. Solution B consisted of about 
0.1mg of artesunate RS per ml of toluene. 
Two microlitres each of Solutions A and B 
were spotted on the TLC and developed in 
the chamber. After removal of plate from the 
chamber, it was air-dried, sprayed with 
anisaldehyade methanol TS, and heated to 
120 
o
C for 5 min. The chromatograms were 
examined in ultraviolet light at a wavelength 
of 254 nm and the Rf values (distance 
travelled by spot / distance travelled by 
solvent front) of the various batches were 
calculated. 
 
Method C: To a quantity of the powdered 
tablets equivalent to 0.1 g of artesunate, 40 
ml of dehydrated ethanol was added, shaken 
and then filtered through a Whatman no.1 
filter paper, discarding the first few mL of the 
filtrate. To half of the filtrate, about 0.5 ml of 
hydroxylamine hydrochloride TS2 and 0.25 
ml of NaOH (~80 g/L) TS were added. The 
mixture was heated in a water bath to boiling, 
cooled and two drops of HCl (~70 g/L) TS 
and two drops of ferric chloride  (50 g/L) TS 
was added. 
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Method D: The remaining filtrate in Method C 
was evaporated on a water bath to a volume 
of about 5ml .  Few drops of the mixture was 
placed on a white porcelain dish and one 
drop of vanillin/sulphuric acid TS2 was added 
and allowed to stand for 30 min.  
 
A sample that contains artesunate yields a 
principal spot on TLC with the same Rf, 
appearance and intensity as the reference 
artesunate (method A), a light red-violet 
colour (method B) and a red colour (method 
D). Failure to yield these results constitutes a 
negative result. 
 
Amodiaquine was identified using United 
States Pharmacopoeia (USP) method B (UV-
VIS absorption) [13]  whereby an amount 
equivalent to 300 mg of amodiaquine was 
transferred to a 250 ml beaker. 100 ml of 
dilute hydrochloric acid (1 in 100) was added 
and heated on a steam bath for about 15 min 
with occasional stirring. The mixture was 
cooled to room temperature and transferred 
to a 200 ml volumetric flask. Dilute 
hydrochloric acid (1 in100) was added to 
make it up to 200 ml and mixed; 10 ml of the 
clear supernatant was mixed with 10 ml of 
dilute hydrochloric acid (1 in 100) in a 125 ml 
separator. It was washed with 20 ml of 
chloroform, the washing discarded, and 4.5ml 
of 1N sodium hydroxide was added followed 
by extraction with four 25 ml portions of 
chloroform. The combined chloroform extract 
portions were further extracted with three 50 
ml portions of dilute hydrochloric acid (1 in 
100). The acid extracts were combined in a 
200 ml volumetric flask, dilute hydrochloric 
acid (1 in 100) was added to volume and 
mixed. A portion (20 ml) of this solution was 
mixed with dilute hydrochloric acid (1 in 100) 
and made up to volume with the latter in a 
100 ml volumetric flask. The absorbance of 
this solution was concomitantly determined 
with a solution of the undried amodiaquine 
reference sample in dilute hydrochloric acid 
(1 in 100) having a known concentration of 15 
µg per ml in 1cm cells at 342 nm with 
ultraviolet spectrophotometer (Hitachi, Japan) 
using dilute hydrochloric acid (1 in 100) as 
blank.        
    
Assay of artesunate and amodiaquine 
tablets 
 
Artesunate tablets were analysed for their 
content of artesunate using titrimetric 
procedure B of IP [12] whereby 50ml of 
neutralized ethanol (ethanol ~ 750g/L 
containing 0.5 mL of phenolphthalein and 
carbonate-free 0.1 mol/l sodium hydroxide 
and shows a faint pink colour) was mixed well 
with a quantity of crushed artesunate tablets 
equivalent to 0.5 g of artesunate and the 
filtrate titrated against sodium hydroxide.  
 
For the amodiaquine assay, the USP  
spectrophotometric procedure (method B for 
identity test described above) was used. Six 
replicate determinations were carried out. 
The quantity in mg, W, of amodiaquine 
hydrochloride present was calculated in the 
portion of tablets taken by the formula: 
 
W = 21.68 C(Au/As) ………………….  (1)  
 
where C = concentration in µg per ml 
(calculated on anhydrous basis) of the 
reference sample; and Au and  
As are the absorbances of the solution 
obtained from the tablets and the standard 
solution, respectively.  
 
Hardness and disintegration tests 
 
BTB 301 hardness tester was employed. 10 
tablets per sample/brand were used for the 
test and mean hardness values (KgF) were 
recorded. For the disintegration test, the 
disintegration time of six tablets per 
batch/brand were determined in distilled 
water maintained at 37 ± 0.5 
0
C using 
Erweka tablet disintegration apparatus, and 




Dissolution tests were carried out on the 
tablets using the USP general method [13] in 
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0.1M HCl (900 ml) with the aid of  Erweka 
DT-D dissolution test apparatus (Erweka, 
U.K.) fitted with a basket rotated at 100 rpm 
for artesunate tablets and 50 rpm for 
amodiaquine tablets as prescribed by IP [12]  
and USP [13],  respectively.  Samples were 
withdrawn from a zone midway between the 
surface of the dissolution medium and the top 
of the rotating basket, and replaced with fresh 
aliquot of dissolution medium, in order to 
maintain sink conditions. 
The samples were filtered and diluted 
appropriately with 0.1N HCl and water for 
artesunate and amodiaquine, respectively. 
The absorbance of the solutions were 
measured at 216nm and 342nm, 
respectively. Drug released (%) against time 
was plotted for each formulation and the t50 
and t75  (time required for 50 % and 75 % of 
drug dissolution, respectively) were 
deriveded from the plots by extrapolation. 
The amount dissolved in 45 and 30 min was 
obtained for each brand of artesunate and 
amodiaquine, respectively. All determinations 




Chi square was used to analyse the effect of 
cost of product brand on quality. Correlation 
analysis was adopted to study the 
interrelationship between various physical 
parameters while the dissolution data were 
analysed using ANOVA. Results are 





Physical and organoleptic properties 
 
The results of physical and organoleptic 
assessment of the label, packaging, etc, of -
artesunate products, Table 1, indicate that 
they were attractively packaged with unique 
identification markings, except samples B2 
and B3 which were poorly packaged and had 
a dull green colour. All the artesunate 
samples were marked with the logo and/or 
brand name of their claimed manufacturer. 
The tablets were odourless with colours 
ranging from white to off-white or a tint of 
yellow. As Table 2 shows, all the 
amodiaquine products were attractively 
packaged; the tablets were yellow in colour, 
scored and also marked with the 
manufacturer’s logo, with the exception of 
sample DD which had no unique logo and 
was not scored. These physical observations 
indicate that all the artesunate tablets, except 
B2, B3 and DD, were satisfactory in 
appearance with actual identification marks 
 
Based on Table 1, thirteen out of the total of 
15 samples of the artesunate brands studied 
contained artesunate in conformity with 
International Pharmacopeia (IP) require-
ments, except B2 and B3 which contained < 
50 % of labelled content. All the artesunate 
brands passed the weight uniformity test as 
no two tablets deviated by more than 10 % 
and none by 20 %. Furthermore, all the 
artesunate tablets had mean diameter within 
the IP limit, and also showed good hardness. 
Five (33 %) of the artesunate tablet samples 
contained artesunate within IP range (90 - 
110 %) of label claim, 8 (53.3 %) exceeded 
the upper limit (> 110 %) and 2 brands, B2 
and B3, (13.3 %) fell well below the lower 
limit.  
 
The unit cost per packet was similar for the 
artesunate products with the substandard 
products costing about as much as the 
genuine ones. There was no statistically 
significant difference (p > 0.05) in cost 
between imported and locally manufactured 
tablets. All amodiaquine tablets had 





Table 2 shows the physicochemical 
properties of amodiaquine tablet brands. All 5 
brands of amodiaquine tablets showed good 
hardness properties and met USP drug 
content requirements of 93 – 107 % of 
labelled content [13]. The cost per unit packet 
of amodiaquine varied much more than that 
of artesunate tablets, with the latter being 
more expensive. 
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A Satisfactory 54.0   108.1±1.4     2.2   9.5±0.0 5.2±0.6 09/08 Aretmed India 
B Satisfactory 59.1   118.3±1.6     2.3 10.2±0.0 5.4±0.6 12/09 Artesunat China 
B1 Satisfactory 56.7   113.5±1.4     2.3 10.1±0.0 5.6±0.9 03/10 Artesunat China 
B2 unsatisfactory 14.2   28.3±1.6        2.3 10.2±0.0 6.6±1.9 08/08 Artesunat China 
B3 unsatisfactory 24.8   49.5±3.4        2.3 10.2±0.0 6.9±1.9 07/09 Artesunat China 
C Satisfactory 53.0   106.1±2.2     2.5 9.5±0.0   7.7±0.4 10/08 Arthlon India 
D Satisfactory 54.4   108.8±2.2     2.4 10.6±0.0 3.8±0.4 11/09 Malasunate China 
E Satisfactory 53.7   107.4±1.6     2.0 8.7±0.1    8.1±1.5 07/08 Arinate Belgium 
F Satisfactory 56.1   112.1±2.6     2.4 9.5±0.0    5.5±2.8 09/09 Vami’s Nigeria 
F1 Satisfactory 56.4   112.8±2.7     2.4 9.5±0.0    5.3±0.9 02/10 Vami’s Nigeria 
G Satisfactory 56.1   112.1±2.6     2.2 9.5±0.0    5.5±1.5 09/08 Lever China 
G1 Satisfactory 57.4   114.8±1.4     2.1 9.3±0.0    5.5±1.3 11/09 Lever China 
H Satisfactory 55.4   110.8±2.6     2.4 9.2±0.0    4.2±1.1 05/08 Malmeter India 
H1 Satisfactory 54.0   108.1±2.6     2.4 9.1±0.0   4.3±0.9 09/08 Malmeter India 
I Satisfactory 57.1   114.2±2.2     2.5 9.6±0.01   5.2±0.5 12/08 Larimal India 
 
a
IP requirement: 90 -110% of amount stated on label (n = 6);    
b
 n =12; 
c
 n= 10 
 
 









rel (%)  















AA 94.3±0.3 9.2±0.8 81.2±1.8 3.7±0.1 4.8±0.5 4.8±0.4 0.5 12/09 Camoquine USA 
BB 94.0±0.5 5.8±0.4 82.8±1.3 3.2±0.1 5.1±0.2 6.4±0.8   0.3 12/08 Larimal India 
CC 94.6±0.4 9.0±0.6 73.3±2.0 5.0±1.0 31.7±1.3 4.9±0.4    0.2 12/09 Timec India 
DD 94.4±0.9 20.7±0.8 82.8±3.8 3.4±0.1 5.9±1.0   4.4±0.7    0.4 10/08 Loquine England 
EE 94.6±1.0 15.8±1.8 81.3±3.9 3.2±0.1   6.2±0.9   4.8±1.0   0.6 3/09 Dart Nigeria 
a 
USP requirement: 93 -107% of amount stated on label (n = 6);  
b
 n= 6  
d
n=10; td = disintegration time; t50 = 
time taken to attain 50 % dissolution; t75 = time taken to attain 75 % dissolution. All brands had satisfactory 
product appearance 
 
Artesunate tablets disintegrated within 12 min 
with the exception of brand B2, one of the 
two substandard samples, which 
disintegrated in 34.8 min; this is higher than 
the official USP limit of 30 min.  However, all 
the brands of amodiaquine tablets 
disintegrated within 21 min which is within the 
USP limit of 30 min. The t50 and t75 (USP 
upper limits of t50 and t75 are 20 and 30 min, 
respectively, beyond which dissolution is 
poor) dissolution values indicate that all the 
tablets also possess good dissolution 
properties except amodiaquine brand CC 
which did not meet the essential minimum 
within 30 min (Figure 3). In addition, the 
amodiaquine brands passed drug 
identification test, as shown in Table 2. 
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time (mins) a 
t50 (min) 
a t75 (min) 
a 
Dissolution in 
45 min (%) 
A 3.8±0.8 2.9±0.1 3.9±0.1 79.0±1.0 
B 3.5±0.5 3.0±0.1 4.0±0.1 89.0±0.9 
B1 3.3±1.0 3.0±0.1 4.0±0.1 93.0±1.1 
B2 34.8±3.3 - - - 
B3 3.8±0.8   - - - 
C 4.2±0.8 2.9±0.1 3.9±0.1 81.0±1.4 
D 3.8±0.8 2.7±0.1 3.3±0.2 92.0±1.2 
E 3.0±0.6 3.0±0.1 4.1±0.1 79.0±1.1 
F 7.7±1.2 2.9±0.2 3.8±0.2 93.00±1.5 
F1 11.7±2.0 2.9±0.2 3.9±0.1 95.0±5.5 
G 3.5±0.8   2.8±0.2 3.6±0.3 89.0±0.9 
G1 3.5±0.8   2.8±0.2 3.6±0.2 88.0±0.8 
H 4.8±0.8   2.8±0.3 3.8+/-0.2 84.0±0.6 
H1 7.7±0.8   2.9±0.1 4.0±0.2 85.0±1.4 
I 4.2±0.8   2.9±0.1 3.9±0.1 84.0±0.8   


















Figure 1: Dissolution profiles of artesunate tablet brands. (a):  = A;   = B;  = C; ◊ = D;  = E;  = F; 
 = G;  = H; and (b):  = I;  = B1;  = F1;  = G1; ◊ = H1 
 
 
Figure 2: Dissolution profiles of amodiaquine 






The results presented in Table 1 indicate that 
a majority (66.7 %) of the artesunate tablets 
studied failed the drug content assay test. 
The identification test (using TLC) revealed 
that artesunate was undetectable in brands 
B2 and B3, due probably to the low content of 
drug. The packaging of the fake products was 
similar to some of the genuine brand, except 
for their colour and unique markings. This 
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deliberately counterfeited. Counterfeiting has 
been reported in a recent survey in south-
east Asia which showed that among 104 
tablet brands presented as artesunate, 38 % 
did not contain artesunate. Magnus et al [14] 
stated in a previous study that counterfeit or 
substandard artemisinin-based derivatives 
were being sold in parts of Africa, presenting 
a potential route for resistance development 
in the future. Also in Cambodia in 1990, 
substandard antimalarials were reported as 
responsible for the deaths of at least 30 
people [15]. The results from this work are 
the first to show, to the best of our 
knowledge, the circulation of substandard 
artesunate tablet in Nigeria. This poses a 
serious health danger as Nigeria, in 2004, 
adopted the use of ACTs, in her national 
antimalarial treatment policy, for 
uncomplicated malaria in accordance with 
WHO guidelines [16]. In view of the health 
implications of counterfeit products, including 
development of resistant strains of 
plasmodium parasites, this calls for proper 
monitoring of all commercial brands of 
artesunate tablets, both locally manufactured 
and imported, including at ports of entry for 
imported products.  
 
Out of the 10 generic products (66.7 %) that 
failed drug content test, 8 were imported 
products and 2 (20 %) were locally 
manufactured (F and F1) as shown in Table 
1. Eight out of these 10 products had excess 
drug (> 110 % of labelled content) and 
although they may be therapeutically 
effective, there could be increased risk of 
toxicity and increased side-effects on 
ingestion. The two products with drug content 
below pharmacopoeial specifications may be 
regarded as substandard and/or counterfeit 
products.  
 
Chi-square analysis of the unit cost of the 
products and physicochemical properties 
revealed that there is no significant 
correlation between cost and the quality of 
artesunate products (p = 0.449) or between 
the quality of the drug and country of 
manufacture (p  = 0.364). 
In the dissolution test, at 45 min, all the 
artesunate products, except B2 and B3 which 
failed the drug content test, released over 75 
% of their drug content (see Table 3, Figure 
1) and thus satisfied the requirements of BP 
[17] which states that the amount of active 
ingredient released in solution for uncoated 
tablets at 45 min should not be less than 75 
% of the labelled strength.  
 
Products F and F1 which are indigenous 
(local) artesunate tablets had comparable 
hardness, longer disintegration times and 
higher amounts of active drug released 
compared to product B which served as the 
reference (Tables 1 and 3). This indicates 





All the five amodiaquine brand products 
studied disintegrated within 21 min (Table 2) 
and thus complied with the USP limit of 30 
min. All the amodiaquine products had good 
hardness properties. There was no 
correlation between tablet hardness and 
disintegration time for these products (p > 
0.05). The drug release profile of three of the 
products (BB, DD and EE) were not 
statistically different (p > 0.05) from  that of 
the reference product AA. However, all but 
one product, CC, satisfied the USP 
requirement of a minimum of 75 % release 




If a particular drug product meets the 
requirements of USP for dissolution and other 
in vitro parameters, it gives assurance that 
the drug will be released satisfactorily from 
the dosage formulation in vivo and should 
lead to good bioavailability. Although most of 
the tested products met compendial 
standards, including content uniformity, 
disintegration and dissolution rates, all the 
products cannot be classified as 
pharmaceutical equivalents. Pharmaceutical 
equivalents are those drug products in 
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identical dosage forms that contain identical 
amounts of the same active drug and that 
meet identical compendial or other applicable 
standards, including potency, content 
uniformity, disintegration time and dissolution 
rate. Hence artesunate products A, C, D, E 
and H1 were pharmaceutical equivalents as 





The detection of substandard and over-
packed artesunate tablets brands and the 
observation that all the products tested had 
different dissolution profiles and 
disintegration rates imply that they were not 
pharmaceutical equivalents. Since 
pharmaceutical equivalence is a basic 
requirement (among other factors) for 
substitution when prescribing and/or 
dispensing drugs, this study shows that 
caution should be applied in substituting 
generic brands of artesunate and 
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